Quick Facts

• Condition Treated: Erectile dysfunction
• Condition Treated: Signs and symptoms of benign prostatic hyperplasia (BPH)
• Benefit: Aids in achieving and maintaining an erection with sexual stimulation
• Benefit: May improve lower urinary tract symptoms associated with BPH

---

Tada 10 (tadalafil) is a prescription medication utilized in the management of two primary health conditions in adult men. The drug is indicated for the treatment of erectile dysfunction (ED), which involves difficulty achieving or maintaining a penile erection sufficient for sexual performance. It works by assisting in the mechanism that increases blood flow to the penis following sexual stimulation, helping to produce and sustain an erection.

Additionally, this medicine is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). BPH is a condition caused by an enlarged prostate, leading to lower urinary tract symptoms such as weak stream, hesitation, and the need to urinate frequently or urgently. The drug helps to improve these symptoms, which can enhance daily comfort and function.

In some cases, the medication is indicated for the treatment of both erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia simultaneously.

The official eligibility profile for Tada 10 (tadalafil) is strictly defined by regulatory authorities and specifies which populations are permitted, restricted, or absolutely prohibited from use.

Populations for Whom Use is Forbidden (Contraindications)

Category	Absolute Prohibition
Co-Medications	Patients using any form of organic nitrate (e.g., nitroglycerin), regularly or intermittently, or a Guanylate Cyclase (GC) Stimulator (e.g., riociguat).
Cardiovascular History	Patients who have had a myocardial infarction within 90 days or a stroke within 6 months [EMA]. Patients with unstable angina or uncontrolled arrhythmias/hypertension.
Hypersensitivity	Patients with known serious hypersensitivity to tadalafil or any of the inactive ingredients.

Restricted or Not-Recommended Use

Category	Use Restriction (Requires Caution)
Organ Function	Severe Hepatic Impairment (Child-Pugh Class C) or Severe Renal Impairment (Creatinine Clearance < 30 mL/min): Use is not recommended or restricted.
Chronic Conditions	Patients with a history of Non-Arteritic Ischemic Optic Neuropathy (NAION) or those with conditions that predispose to priapism (e.g., sickle cell anemia) or anatomical penile deformity.

Age and Sex Eligibility

The medicine is indicated exclusively for use in adult males (18 years and older). It is not indicated for use in females (including during pregnancy or lactation) or in pediatric patients as safety and efficacy have not been established in these groups. No dose adjustment is required in elderly men based on age alone.

Interactions with other medicines and products

Contraindicated Combinations

The co-administration of Tada 10 is contraindicated (absolutely prohibited) with two classes of medicines due to the risk of severe, life-threatening hypotension resulting from additive blood pressure-lowering effects.

Medicine Category	Interaction Basis	Mandatory Restriction
Organic Nitrates (All forms)	Pharmacodynamic Reinforcement	Co-administration is contraindicated.
GC Stimulators (e.g., Riociguat)	Pharmacodynamic Reinforcement	Co-administration is contraindicated.

In a medical emergency where nitrate use is required, official labeling mandates that at least 48 hours must elapse since the last Tadalafil dose.

Other Clinically Significant Interactions

The primary elimination pathway for Tada 10 is through the Cytochrome P450 3A4 (CYP3A4) enzyme. Substances that inhibit this enzyme, such as Ketoconazole or Ritonavir, increase Tadalafil exposure (AUC). This pharmacokinetic interaction requires specific maximum dosage restrictions to manage increased drug levels. Conversely, potent CYP3A4 inducers, such as Rifampin, decrease Tadalafil exposure and are generally not recommended due to reduced efficacy.

Tada 10 may potentiate the hypotensive effects of other blood pressure-lowering agents, including alpha-blockers (e.g., Doxazosin) and antihypertensives. Furthermore, substantial consumption of alcohol (ge 5 units) is documented to increase the risk of orthostatic hypotension. Use in patients with severe renal or hepatic impairment is officially not recommended due to the risk of increased drug exposure and reduced clearance.

Tada 10 works exclusively by modulating the biological processes that control the tension of smooth muscle cells, resulting in a change in localized blood flow. The mechanism is strictly dependent on the body's natural signaling systems and does not independently initiate the physiological response.

---

Selective Blockade of the PDE5 Enzyme

The action is defined at the molecular level by Tadalafil's role as a selective inhibitor of the Phosphodiesterase type 5 (PDE5) enzyme. This enzyme is naturally responsible for the hydrolysis, or breakdown, of the key cellular messenger cyclic Guanosine Monophosphate (cGMP). By blocking this enzymatic action, Tadalafil facilitates the accumulation of cGMP, which is the essential initiating event for subsequent downstream modulation of vascular smooth muscle tone.

---

cGMP-Driven Smooth Muscle Relaxation

This increased cGMP concentration engages the Nitric Oxide (NO)-cGMP signaling cascade. Elevated cGMP levels trigger a reaction within the smooth muscle cells, culminating in a crucial decrease in intracellular calcium ( Ca^2+). This functional consequence is the targeted relaxation of smooth muscle and subsequent localized vasodilation, resulting in an increase in localized blood flow only in the tissues where the physiological NO signal has been naturally initiated.

How to Use Tada 10

The administration of Tada 10 (tadalafil) is based on two primary dosing protocols: use as-needed or use once-daily. The medicine is supplied as a film-coated tablet and is always taken via the oral route. The tablet must be swallowed whole, and it should not be broken, crushed, or split before consumption.

---

Dosing Patterns and Frequency

There are two high-level patterns for use, associated with the indication and clinical context:

Usage Pattern	Standard Starting Dose	Maximum Dose	Maximum Frequency
As-Needed	10 mg	20 mg	Once every 24 hours
Once-Daily	2.5 mg	5 mg	Once every 24 hours

For the once-daily regimen, the tablet should be taken at approximately the same time each day, regardless of the timing of sexual activity. The dose for benign prostatic hyperplasia (BPH) is typically 5 mg once daily.

---

Administration Context and Adjustments

The administration of Tada 10 is not dependent on food intake; it may be taken either with or without a meal. No initial dose adjustment is required for older adults based on age alone. However, there are specific dose and frequency adjustments for adult patients with certain degrees of renal or hepatic impairment. For instance, in severe renal impairment, the maximum dose for as-needed use is reduced to 5 mg and frequency is limited to no more than once every 72 hours. If a dose in the once-daily regimen is missed, the patient should simply take the next scheduled dose and should not take a double dose.

Research Evidence / Overview of Studies for Tada 10 (Tadalafil)

This section describes the structure of the clinical research conducted with Tadalafil, including the types of studies, the outcomes that were measured, and what remains to be fully characterized in the evidence landscape.

---

Evidence for Use in Erectile Dysfunction (ED)

The main body of research for Tadalafil in men with Erectile Dysfunction (ED) was evaluated using controlled clinical studies, mostly Randomized Controlled Trials (RCTs). The studies were designed to assess outcomes related to physical discomfort and outcomes reflecting daily functioning by monitoring changes in scores on patient-reported questionnaires. Research also explored populations with ED associated with conditions where symptoms may vary in intensity, such as diabetes and hypertension.

When compared to a placebo, the studies data show patterns related to changes in the functional activity measurements over the short-term study periods. While evidence provides context, it does not determine whether an individual will respond similarly.

---

Evidence for Use in Benign Prostatic Hyperplasia (BPH) Symptoms

Research on Tadalafil for the signs and symptoms of Benign Prostatic Hyperplasia (BPH) also relies on placebo-controlled RCTs. These studies primarily monitored subjective outcomes, such as patient-reported outcomes describing perceived discomfort. The measurement instruments included the International Prostate Symptom Score (IPSS). In these trials, the studies reported how symptoms evolved in the observed populations by recording the measurements of IPSS scores when compared to the placebo group.

However, research also examined objective measures like the maximum urinary flow rate (boldsymbolQmax). The documented findings for boldsymbolQmax were mixed and evidence quality varies across studies on this specific, objective measurement.

---

What is Still Uncertain About Tadalafil Research

Key uncertainties in the overall evidence landscape include the long-term observation of outcomes beyond two years, as this data is currently limited. Furthermore, comparative evidence is lacking in head-to-head trials against other treatments in the same class, and the sample sizes were modest for some subgroups. Research is ongoing to address these limitations.

Common questions about Tada 10 (FAQ)

Q: What is the main reason Tada 10 is prescribed?

A: The active ingredient in Tada 10 (tadalafil) is officially approved to treat Erectile Dysfunction (ED) and the signs and symptoms of Benign Prostatic Hyperplasia (BPH). It is also approved for treating Pulmonary Arterial Hypertension (PAH), which is a specific type of high blood pressure affecting the lungs.

Q: Is Tada 10 considered a generic or brand-name medicine?

A: Tada 10 contains the generic active ingredient, tadalafil. This ingredient is also widely known by its major brand names, such as Cialis and Adcirca. The official regulatory documents confirm that the generic and brand-name versions contain the same medicinal substance.

Q: What is the difference between Tada 10 and Cialis?

A: Cialis is a brand name for the active ingredient tadalafil, which is the component in Tada 10. The products contain the same medicinal substance.

Q: Do you need a prescription to get Tada 10?

A: Yes. According to major regulatory authorities, the active ingredient in Tada 10 (tadalafil) is classified as a prescription-only medication. This requires authorization from a healthcare provider before the medicine can be dispensed.

Q: How long does it typically take for the effects of Tada 10 to start?

A: Official product information indicates that when Tada 10 is taken on an as-needed basis, the medicine usually begins to show effects within 30 minutes of consumption. Individual experience may vary.

Q: What is the expected duration of effect after taking Tada 10?

A: Studies on the active ingredient have been associated with a duration of effect of up to 36 hours following a single dose. This extended action is noted in pharmacological studies.

Q: Does Tada 10 need to be taken every day?

A: No, it does not have to be taken daily for all conditions. Official regulatory documents describe two dosing protocols: use once a day for daily consistency, or use as needed prior to activity. The choice between these frequencies is based on the condition being treated and is defined in the official prescribing information.

Q: Are there any side effects of Tada 10 that are known to be long-term?

A: Clinical studies conducted over periods of up to two years did not show that the medicine’s primary treatment effect diminished over time. Research also continues to track outcomes in populations over time, beyond the initial study periods.

Q: Are there any age restrictions for taking Tada 10?

A: Yes. Tadalafil is indicated exclusively for use in adults, meaning individuals 18 years and older. Because safety and effectiveness have not been established in this group, use in pediatric patients is not indicated.

Q: How does the mechanism of Tada 10 differ from other treatments?

A: Tada 10 is classified as a PDE5 inhibitor, which is the same class as several other treatments. While its core function is similar to others in the class, pharmacological studies describe an extended duration of action in the body.

Q: Has there been any research on Tada 10 in women?

A: Tada 10 is not indicated for use in women for its most common purposes. However, the active ingredient has been studied in females for the treatment of Pulmonary Arterial Hypertension (PAH). Official labeling states that the drug is not indicated for use during pregnancy or lactation due to insufficient safety data.

Q: Is the research for Tada 10 published in major medical journals?

A: Yes. The clinical data and pivotal efficacy studies that led to the regulatory approval of tadalafil have been published in and referenced across established medical and scientific journals.

Q: Does taking Tada 10 impact fertility or sperm count?

A: Regulatory information indicates that only a very minimal amount of the administered dose of tadalafil has been found to appear in the semen of healthy subjects (less than 0.0005%).

Q: Why do some people experience back pain after taking Tada 10?

A: Back pain is listed as a common adverse reaction in official safety documents. Although the precise cause is not fully established, it is believed to be a characteristic effect common to this class of medicine. The pain is typically described as mild to moderate and is often transient, as noted in the product safety information.

Q: Is Tada 10 used for purposes other than what it is mainly known for?

A: Yes. While widely known for treating Erectile Dysfunction, the medicine is also approved to treat the signs and symptoms of Benign Prostatic Hyperplasia (BPH) and Pulmonary Arterial Hypertension (PAH).

Q: Is it possible to become resistant to the effects of Tada 10 over time?

A: Clinical studies that monitored treatment effects over periods of up to two years did not observe a decrease or loss of the medicine’s effectiveness over time in the populations studied.

Q: Is Tada 10 safe to take with common pain relievers like ibuprofen?

A: Regulatory documents do not specifically list non-prescription pain relievers like ibuprofen as being contraindicated. However, due to its vasodilatory properties, caution is noted regarding combining it with any other medication.

Q: Does the manufacturer of Tada 10 provide an official patient information leaflet?

A: Yes. Regulatory guidelines require manufacturers to provide official patient information and other patient labeling for this medicine. This is designed to give users essential facts about the product.

Q: Can Tada 10 be taken with other medications for the prostate?

A: Tada 10 is often used for BPH symptoms. Regulatory documents include warnings regarding co-administration with certain other blood pressure-lowering agents, such as alpha-blockers, due to the potential for additive effects on blood pressure.

Q: How does Tada 10 affect blood pressure?

A: As a result of its mechanism of action, Tada 10 has mild systemic vasodilatory properties, meaning it causes blood vessels to widen. This effect may result in transient, temporary decreases in blood pressure. For this reason, specific warnings related to cardiovascular conditions are included in the product labeling.

Q: What is the maximum time Tada 10 stays in the body?

A: Pharmacological studies indicate that the mean terminal half-life of the active ingredient is approximately 17.5 hours in healthy individuals. The half-life describes the time it takes for half of the drug to be eliminated from the body.

Q: What is the official chemical name of the active ingredient in Tada 10?

A: The active ingredient is Tadalafil, which is a Pyrazinopyrimidine derivative. The full, formal chemical name is complex, but it is the unique chemical structure that dictates its selective action on the PDE5 enzyme.

Q: What are the signs of a serious allergic reaction to Tada 10?

A: Serious allergic reactions are rare but have been reported in post-marketing surveillance. These include severe skin conditions like Stevens-Johnson syndrome, as well as the sudden swelling of the lips, mouth, throat, or tongue.

How to Store and Dispose of Tada 10 (Tadalafil)

Official regulatory information mandates specific conditions for the storage and disposal of Tadalafil tablets to maintain their stability and safety.

Storage Requirements

Condition	Official Requirement
Temperature	Store at room temperature, typically 20 C to 25 C (68 F to 77 F); do not store above 30 C and keep from freezing.
Protection	Keep the medicine in its original package and a closed container to protect it from heat, moisture, and light.
Safety	The product must be kept out of the sight and reach of children.

Disposal Instructions

Any unused or expired Tadalafil must be disposed of in accordance with local requirements. Official guidance advises against flushing medications down the toilet or disposing of them in household waste without first using an approved method, such as a community drug take-back program.